



Study	Sample size	Proportion (%)	95% CI
Arabi et al. 2009	25	52.000	31.306 to 72.203
Basil et al. 2000	70	87.143	76.991 to 93.949
Black et al. 2006	93	82.796	73.570 to 89.834
Nagle et al. 2018	163	86.503	80.281 to 91.344
Ruiz et al. 2014	64	78.125	66.030 to 87.493
Talhok et al. 2016	12	75.000	42.814 to 94.514
Total (fixed effects)	427	82.232	78.300 to 85.717
Total (random effects)	427	79.430	71.500 to 86.357
Q		15.942	
DF		5	
Significance level		P = 0.007	
I ² (inconsistency)	(A)	68.640%	
95% CI for I ²		25.980 to 86.710	



Study	Sample size	Proportion (%)	95% CI
Arabi et al. 2009	25	48.000	27.797 to 68.69
Basil et al. 2000	70	12.857	6.051 to 23.009
Black et al. 2006	93	17.204	10.166 to 26.43
Nagle et al. 2018	134	16.418	10.584 to 23.79
Ruiz et al. 2014	60	16.667	8.293 to 28.522
Talhok et al. 2016	12	25.000	5.486 to 57.186
Total (fixed effects)	394	18.349	14.677 to 22.49
Total (random effects)	394	20.168	13.746 to 27.46
Q		13.107	
DF		5	
Significance level	(B)	P = 0.022	
I ² (inconsistency)		61.850%	
95% CI for I ²		7.020 to 84.350	



Supplementary Fig. S7. International Federation of Gynecology and Obstetrics stage analysis in mismatch repair deficiency mutant endometrial carcinoma [4,6,13,14,21,24]: (A) stage I–II and (B) stage III–IV. CI, confidence interval.